Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 10/2014

01-10-2014 | Microvascular Complications—Neuropathy (D Ziegler, Section Editor)

Is There an Association Between Diabetic Neuropathy and Low Vitamin D Levels?

Authors: Zsuzsanna Putz, Tímea Martos, Nóra Németh, Anna Erzsébet Körei, Orsolya Erzsébet Vági, Miklós Soma Kempler, Péter Kempler

Published in: Current Diabetes Reports | Issue 10/2014

Login to get access

Abstract

In the past few years, the effects of vitamin D that go beyond its relationship with bone metabolism have come into the focus of scientific attention. Research concerning diabetes and its complications has become a public health priority. An increasing number of reports link vitamin D deficiency to diabetes; however, so far, there has only been limited and contradictory data available on the correlation between diabetic peripheral neuropathy and vitamin D. Studies of people with type 2 diabetes confirmed the relationship between vitamin D deficiency and neuropathy incidence as well as the severity of the symptoms caused by neuropathy. The latest studies are also suggesting a relationship between the incidence of plantar ulcers and vitamin D deficiency.
Literature
1.
Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S, Kiefte-de-Jong JC, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ. 2014;348:g1903.PubMedCrossRefPubMedCentral
2.
International Diabetes Federation. IDF Diabetes Atlas 6th edn. Brussels: International Diabetes Federation; 2013.
3.
Wolden-Kirk H, Rondas D, Bugliani M, Korf H, Van Lommel L, Brusgaard K, et al. Discovery of molecular pathways mediating 1,25-dihydroxyvitamin D3 protection against cytokine-induced inflammation and damage of human and male mouse islets of Langerhans. Endocrinology. 2014;155(3):736–47.PubMedCrossRef
4.
Raab J, Giannopoulou EZ, Schneider S, Warncke K, Krasmann M, Winkler C, et al. Prevalence of vitamin D deficiency in pre-type 1 diabetes and its association with disease progression. Diabetologia. 2014;57(5):902–8.PubMedCrossRef
5.
Scragg R, Sowers M, Bell C. Third National Health and Nutrition Examination Survey, serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27(12):2813–8.PubMedCrossRef
6.
Putz Z, Hermányi Z, Tóth N, Istenes I, Keresztes K, Jermendy G, et al. A distalis típusú, sensoros neuropathia diagnosztikája a diabetológiai gyakorlatban. Diabetologia Hungarica. 2008;16:157–64.
7.
Zs P, Kempler P, Jermendy G. Diabetes specifikus szövődmények prediabetesben. Orv Hetil. 2009;150(47):2139–45.CrossRef
8.
Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev. 1994;10(4):339–83.PubMedCrossRef
9.
Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2005;29:21–30.PubMedCrossRef
10.
Freedman DM, Dosemeci M, Alavanja MC. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case–control study based on death certificates. Occup Environ Me. 2000;57:418–21.CrossRef
11.
Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296:2832–8.PubMedCrossRef
12.
van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Taylor BV, Kilpatrick T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol. 2007;254:581–90.PubMedCrossRef
13.
Simpson Jr S, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, et al. I., Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010;68:193–203.PubMed
14.
Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna JP, Lilius EM, Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008;79:152–7.PubMedCrossRef
15.
Mowry EM, Krupp LB, Milazzo M, Chabas D, Strober JB, Belman AL, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol. 2010;67:618–24.PubMed
16.
Correale J, Ysrraelit MC, Gaitán MI. Immunmodulatory effects of vitamin D in multiple sclerosis. Brain. 2009;132:1146–60.PubMedCrossRef
17.
Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, et al. A phase I/II doseescalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010;74:1852–9.PubMedCrossRefPubMedCentral
18.
Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, et al. Efficacy of vitamin D(3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci. 2011;311:44–9.PubMedCrossRef
19.
Llewellyn DJ, Lang IA, Langa KM, Muniz-Terrera G, Phillips CL, Cherubini A, et al. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med. 2010;170(13):1135–41.PubMedCrossRefPubMedCentral
20.
Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Sääksjärvi K, Heliövaara M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol. 2010;67(7):808–11.PubMedCrossRefPubMedCentral
21.
Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, et al. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 2013;81(17):1531–7.PubMedCrossRef
22.
Lee P, Chen R. Vitamin D as an analgesic for patients with type 2 diabetes and neuropathic pain. Arch Intern Med. 2008;168:771–2.PubMedCrossRef
23.
Shebab D, Al-Jarallah K, Mojiminiyi OA, Al Mohamedy H, Abdella NA. Does vitamin D deficiency play a role in peripheral neuropathy in type 2 diabetes? Diabet Med. 2012;29:43–9.CrossRef
24.
Valensi P, Devehat C, Richard JL, Farez C, Khodabandehlou T, Rosenbloom RA, et al. A multicenter double blind, safety study of QR-333 for treatment of symptomatic diabetic peripheral neuropathy: a preliminary report. J Diabetes Complicat. 2005;19:247–53.PubMedCrossRef
25.••
Soderstrom LH, Johnson SP, Diaz VA, Mainous 3rd AG. Association between vitamin D and diabetic neuropathy in a nationally reperesentative sample: results from 2001–2004 NHANES. Diabet Med. 2012;29:50–5. This study analyses a representative sample, proving that Vitamin D is insufficiency associated with self-reported peripheral neuropathy symptoms. PubMedCrossRefPubMedCentral
26.
Skalli S, Muller M, Pradines S, Halimi S, Wion-Barbot N. Vitamin D deficiency and peripheral diabetic neuropathy. Eur J Intern Med. 2012;23:67–8.CrossRef
27.
Ahmadieh H, Azar ST, Lakkis N, Arabi A. Hypovitaminosis D in patients with type 2 diabetes mellitus: a relation to disease control and complications. ISRN Endocrinol. 2013;22(2013):641098.
28.
Riaz S, Malcangio M, Miller M, Tomlinson DR. A vitamin D3 derivative (CB1093) induces nerve growth factor and prevents neurothrophic deficits in streptozotocin-diabetic rats. Diabetologia. 1999;42:1308–13.PubMedCrossRef
29.
Riaz S, Tomlinson DR. Pharmacological modulation of nerve growth factor synthesis: a mechanistic comparison of vitamin D receptor and beta(2)-adrenoreceptor agonists. Brain Res Mol. 2000;85:179–88.CrossRef
30.
Filipović N, Ferhatović L, Marelja I, Puljak L, Grković I. Increased vitamin D receptor expression in dorsal root ganglia neurons of diabetic rats. Neurosci Lett. 2013;9(549):140–5.CrossRef
31.
Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculosceletal pain. Mayo Clin Proc. 2003;78:1463–70.PubMedCrossRef
32.
Bell DSH, Reversal of the symptoms of diabetic neuropathy through correction of vitamin D deficiency in a type 1 diabetic patient. Case Report in Endocrinology, 2012: p. 1–3.
33.
Bell DSH. Protean manifestations of vitamin D deficiency, part 2: deficiency and its association with autotoimmune disease, cancer, infection, asthma, dermopathies, insulin resistance, and type 2 diabetes. South Med J. 2011;335–339:335–9.CrossRef
34.
Van Etten E, Branisteanu DD, Verstuyf A, Waer M, Bouillon R, Mathieu C. Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation. 2000;69:1932–42.PubMedCrossRef
35.•
Zubair M, Malik A, Meerza D, Ahmad J. 25-hydroxyvitamin D [25(OH)D] levels and diabetic foot ulcer: is there any relationship? Diabetes Metab Synd. 2013;7:148–53. Diabetic foot ulcer is a burden for the developed industrial countries, nearly half of all lower-leg amputations of a non-traumatic origin are performed on patients with diabetes. Vitamin D have a possible effect in decreasing this huge number. CrossRef
36.
Hutchinson MS, Figenschau Y, Njølstad I, Schirmer H, Jorde R. Serum 25-hydroxyvitamin D levels are inversely associated with glycated haemoglobin (HbA(1c)). The Tromsø Study. Scand J Clin Lab Invest. 2011;71(5):399–406.PubMedCrossRef
37.
Zoppini G, Galletti A, Targher G, Brangani C, Pichiri I, Negri C, et al. Glycated haemoglobin is inversely related to serum vitamin D levels in type 2 diabetic patients. PLoS One. 2013;8(12):e82733.PubMedCrossRefPubMedCentral
Metadata
Title
Is There an Association Between Diabetic Neuropathy and Low Vitamin D Levels?
Authors
Zsuzsanna Putz
Tímea Martos
Nóra Németh
Anna Erzsébet Körei
Orsolya Erzsébet Vági
Miklós Soma Kempler
Péter Kempler
Publication date
01-10-2014
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 10/2014
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-014-0537-6

Other articles of this Issue 10/2014

Current Diabetes Reports 10/2014 Go to the issue

Psychosocial Aspects (KK Hood, Section Editor)

Motivational Interviewing to Promote Adherence Behaviors in Pediatric Type 1 Diabetes

Diabetes and Other Diseases-Emerging Associations (JJ Nolan, Section Editor)

The Epidemiology of Diabetes and Cancer

Microvascular Complications—Neuropathy (D Ziegler, Section Editor)

The Role of Sodium Channels in Painful Diabetic and Idiopathic Neuropathy

Invited Commentary

Non-Proteinuric Diabetic Nephropathy

Psychosocial Aspects (KK Hood, Section Editor)

Neurocognitive Outcomes in Pediatric Diabetes: a Developmental Perspective

Transplantation (A Pileggi, Section Editor)

New Insight on Human Type 1 Diabetes Biology: nPOD and nPOD-Transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits